Dayvigo™ (lemborexant) – New drug approval
December 20, 2019 - Eisai announced the FDA approval of Dayvigo (lemborexant), for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance..
Download PDF
